



## **2024 PRIOR AUTHORIZATION CRITERIA**

### **Essential Rx (PPO)**

Aspirus Health Plan requires your provider to get prior authorization for certain drugs. This means that you'll need to get approval from us before you fill your prescriptions. If you don't get approval, Aspirus Health Plan may not cover the drug.

**Effective:** 10/01/2024

## **Notice of Nondiscrimination**

Aspirus Health Plan complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex. Aspirus Health Plan does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

We provide aids and services at no charge to people with disabilities to communicate effectively with us, such as TTY line, or written information in other formats, such as large print.

If you need these services, contact us at **715-631-7411 (voice)** or toll free at **1-855-931-4850 (voice)**, **715-631-7413 (TTY)**, or **1-855-931-4852 (TTY)**.

We provide language services at no charge to people whose primary language is not English, such as qualified interpreters or information written in other languages.

If you need these services, contact us at the **number on the back of your membership card** or **715-631-7411** or toll free at **1-855-931-4850 (voice)**; **715-631-7413** or toll free at **1-855-931-4852 (TTY)**.

If you believe that Aspirus Health Plan has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability or sex, you can file an oral or written grievance.

### Oral grievance

If you are a current Aspirus Health Plan member, please call the number on the back of your membership card. Otherwise please call **715-631-7411** or toll free at **1-855-931-4850 (voice)**; **715-631-7413** or toll free at **1-855-931-4852 (TTY)**. You can also use these numbers if you need assistance filing a grievance.

### Written grievance

#### *Mailing Address*

Attn: Appeals and Grievances

Aspirus Health Plan

P.O. Box 51

Minneapolis, MN 55440

Email: [cagMA@aspirushealthplan.com](mailto:cagMA@aspirushealthplan.com)

Fax: 715-631-7439

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at:

U.S. Department of Health and Human Services

200 Independence Avenue SW

Room 509F, HHH Building

Washington, D.C. 20201

1-800-368-1019, 1-800-537-7697 (TDD)

Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 715-631-7411/1-855-931-4850 (TTY: 715-631-7413/1-855-931-4852).

LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 715-631-7411/1-855-931-4850 (TTY: 715-631-7413/1-855-931-4852).

XIYYEEFFANNAA: Afaan dubbattu Oroomiffa, tajaajila gargaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 715-631-7411/1-855-931-4850 (TTY: 715-631-7413/1-855-931-4852).

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 715-631-7411/1-855-931-4850 (TTY: 715-631-7413/1-855-931-4852).

注意: 如果您使用繁體中文, 您可以免費獲得語言援助服務。請致電 715-631-7411/1-855-931-4850 (TTY: 715-631-7413/1-855-931-4852)。

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 715-631-7411/1-855-931-4850 (телетайп: 715-631-7413/1-855-931-4852).

ໂປດຊາບ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສັງຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທ 715-631-7411/1-855-931-4850 (TTY: 715-631-7413/1-855-931-4852).

ማስታወሻ: የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም እርዳታ ድርጅቶቻችን በነጻ ሊያገለግሉት ተዘጋጅተዋል። ወደ ሚክተሎው ቁጥር ይደውሉ 715-631-7411/1-855-931-4850 (መስማት ስተሳናቸው: 715-631-7413/1-855-931-4852).

ဝတ်သည့်ဝတ်သုံး-နမူနာကတိ ကညီ ကျိန်အယိ, နမူနာ ကျိန်အတတ်မစာလော တလက်ဘျက်လက်စွဲ နီတင်ဘတ်သုန့်လီ. ကိ: 715-631-7411/1-855-931-4850 (TTY: 715-631-7413/1-855-931-4852).

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 715-631-7411/1-855-931-4850 (TTY: 715-631-7413/1-855-931-4852).

ប្រយ័ត្ន: បើសិនជាអ្នកនិយាយភាសាអង់គ្លេស, រសវាជំនួយវេជ្ជកម្មភាសា ដោយមិនគិតល្អល គឺអាចមានសំរាប់អ្នក។ ចូរ ទូរស័ព្ទ 715-631-7411/1-855-931-4850 (TTY: 715-631-7413/1-855-931-4852)។

ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم (715-631-7411/1-855-931-4850 (رقم هاتف الصم والبكم: 715-631-7413/1-855-931-4852).

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 715-631-7411/1-855-931-4850 (ATS : 715-631-7413/1-855-931-4852).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 715-631-7411/1-855-931-4850 (TTY: 715-631-7413/1-855-931-4852) 번으로 전화해 주십시오.

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 715-631-7411/1-855-931-4850 (TTY: 715-631-7413/1-855-931-4852).

# **ABIRATERONE**

---

## **MEDICATION(S)**

ABIRATERONE ACETATE

## **PA INDICATION INDICATOR**

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

## **OFF LABEL USES**

Prostate Cancer-Regional Risk Group, Prostate cancer-very-high-risk group, Prostate cancer-radical prostatectomy

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

Prostate Cancer-Metastatic, Castration-Resistant (mCRPC)-Approve if abiraterone is being used in combination with prednisone or dexamethasone and the medication is concurrently used with a gonadotropin-releasing hormone (GnRH) agonist, or the medication is concurrently used with Firmagon or the patient has had a bilateral orchiectomy. Prostate cancer-metastatic, castration-sensitive (mCSPC)- approve if the medication is used in combination with prednisone and the medication is concurrently used with a GnRH agonist or concurrently used with Firmagon or the patient has had a bilateral orchiectomy. Prostate Cancer - Regional Risk Group - Approve if the patient meets all of the following criteria (A, B, and C): A)abiraterone is used in combination with prednisone AND B) Patient has regional lymph node metastases and no distant metastases AND C) Patient meets one of the following criteria (i, ii or iii): i.abiraterone with prednisone is used in combination with GnRH agonist OR

ii. Patient has had a bilateral orchiectomy OR iii. the medication is used in combination with Firmagon. Prostate cancer-very-high-risk-group-approve if according to the prescriber the patient is in the very-high-risk group, the medication will be used in combination with external beam radiation therapy and the patient meets one of the following criteria (i, ii or iii): i. abiraterone is used in combination with GnRH agonist OR ii. Patient has had a bilateral orchiectomy OR iii. the medication is used in combination with Firmagon. Prostate cancer-radical prostatectomy-approve if the medication is used in combination with prednisone, the patient has prostate specific antigen (PSA) persistence or recurrence following radical prostatectomy, patient has pelvic recurrence, the medication will be used concurrently with GnRH agonist, Firmagon or the patient has had a bilateral orchiectomy.

**PART B PREREQUISITE**

N/A

# **ACTEMRA**

---

## **MEDICATION(S)**

ACTEMRA 162 MG/0.9ML SOLN PRSYR, ACTEMRA ACTPEN

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For rheumatoid arthritis (initial requests): Two of the following were ineffective or not tolerated: a) Enbrel, b) Humira or Hadlima, c) Rinvoq OR d) Xeljanz. For polyarticular juvenile idiopathic arthritis (initial requests): Two of the following were ineffective or not tolerated: a) Humira or Hadlima, b) Enbrel OR c) Xeljanz. For giant cell arteritis (all requests): Trial of other agents not required. For systemic sclerosis-associated interstitial lung disease (initial requests): a) Diagnosis is confirmed with documentation provided of both of the following: i) HRCT scan AND ii) pulmonary function tests AND b) Trial of mycophenolate was ineffective or not tolerated. For systemic juvenile idiopathic arthritis (all requests): Trial of other agents not required. For continuation requests (all diagnoses): Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

For rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and giant cell arteritis: Prescribed by, or in consultation with, a rheumatology specialist. For systemic sclerosis-associated interstitial lung disease: Prescribed by, or in consultation with, a pulmonologist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

**PART B PREREQUISITE**

N/A

# **ACTIMMUNE**

---

## **MEDICATION(S)**

ACTIMMUNE

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A



# **ADBRY**

---

## **MEDICATION(S)**

ADBRY 150 MG/ML SOLN PRSYR

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For atopic dermatitis (initial requests): Two of the following were ineffective or not tolerated: a) a medium to very high potency topical steroid, b) a topical calcineurin inhibitor OR c) an oral immunosuppressant. For atopic dermatitis (continuation requests): Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

For atopic dermatitis: Prescribed by, or in consultation with, an allergist, immunologist, or dermatologist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

For atopic dermatitis (initial requests): Member has moderate to severe atopic dermatitis defined as: 1) One of the following: a) body surface area involvement of 10 percent or more OR b) Chart documentation is provided of severity with involvement of the face, head, neck, hands, feet, groin, or intertriginous areas. AND 2) At least two (2) of the following: a) intractable pruritus (itching), b) cracking and oozing/bleeding of skin OR c) impaired activities of daily living. For atopic dermatitis (all requests): Will not be used in combination with another targeted immunomodulator product for the prescribed indication.

**PART B PREREQUISITE**

N/A

## **ADCIRCA**

---

### **MEDICATION(S)**

ALYQ, TADALAFIL (PAH)

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Diagnosis confirmed by right heart catheterization.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# **ADEMPAS**

---

## **MEDICATION(S)**

ADEMPAS

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For all indications: Diagnosis confirmed by right heart catheterization. For pulmonary arterial hypertension: Both of the following were ineffective or not tolerated: one ERA (ambrisentan, bosentan or macitentan (Opsumit)) AND one PDE5-inhibitor (sildenafil or tadalafil). C) For persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4): Trial of other agents not required.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **AFINITOR**

---

## **MEDICATION(S)**

EVEROLIMUS 10 MG TAB, EVEROLIMUS 2 MG TAB SOL, EVEROLIMUS 2.5 MG TAB, EVEROLIMUS 3 MG TAB SOL, EVEROLIMUS 5 MG TAB, EVEROLIMUS 5 MG TAB SOL, EVEROLIMUS 7.5 MG TAB, TORPENZ

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **AKEEGA**

---

## **MEDICATION(S)**

AKEEGA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# ALECENSA

---

## MEDICATION(S)

ALECENSA

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

Documentation is provided of ALK-positive disease.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# ALUNBRIG

---

## MEDICATION(S)

ALUNBRIG

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

Documentation is provided of ALK-positive disease.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A



# ARCALYST

---

## **MEDICATION(S)**

ARCALYST

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# AUGTYRO

---

## **MEDICATION(S)**

AUGTYRO

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of showing one of the following a) ROS1-positive disease. or b) NTRK gene fusion mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# AUSTEDO

---

## **MEDICATION(S)**

AUSTEDO, AUSTEDO XR 12 MG TAB ER 24H, AUSTEDO XR 24 MG TAB ER 24H, AUSTEDO XR 30 MG TAB ER 24H, AUSTEDO XR 36 MG TAB ER 24H, AUSTEDO XR 42 MG TAB ER 24H, AUSTEDO XR 48 MG TAB ER 24H, AUSTEDO XR 6 MG TAB ER 24H, AUSTEDO XR PATIENT TITRATION 6 & 12 & 24 MG TBER THPK

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For tardive dyskinesia (initial requests): A) One of the following: i) Member has failed to respond to a change in current antidopaminergic therapy OR ii) Member is unable to switch current antidopaminergic therapy OR iii) Member has symptoms of tardive dyskinesia and is not using antidopaminergic therapy AND B) Member has a functional disability due to tardive dyskinesia. For chorea associated with Huntington's disease (initial requests): Trial of other agents not required. For continuation requests (all diagnoses): Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Prescribed by, or in consultation with, a neurologist or psychiatrist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# AYVAKIT

---

## MEDICATION(S)

AYVAKIT

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

For unresectable or metastatic gastrointestinal stromal tumor: Documentation is provided of PDGFRA exon 18 mutation.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# **BALVERSA**

---

## **MEDICATION(S)**

BALVERSA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of susceptible FGFR3 genetic alteration.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **BANZEL**

---

## **MEDICATION(S)**

RUFINAMIDE

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Trial of at least one anti-epileptic medication was ineffective or not tolerated.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Prescribed by a neurologist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **BENLYSTA**

---

## **MEDICATION(S)**

BENLYSTA 200 MG/ML SOLN A-INJ, BENLYSTA 200 MG/ML SOLN PRSYR

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For systemic lupus erythematosus initial requests: Two of the following were ineffective or not tolerated: a) hydroxychloroquine, b) methotrexate, c) azathioprine, d) mycophenolate OR e) a corticosteroid. For all requests: Prescriber attests that member does not have severe active CNS lupus AND member is not taking other biologics. For continuation requests (all diagnoses): Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Prescribed by, or in consultation with, a rheumatology specialist, nephrologist, or dermatologist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

For lupus erythematosus initial therapy: Diagnosis of active systemic lupus erythematosus is confirmed by one of the following: A) anti-double stranded DNA value greater than 30 IU/mL OR B) low complement (C3/C4) OR C) positive for anti-Smith antibodies. For systemic lupus erythematosus (all requests): Will not be given in combination with other biologics. For active lupus nephritis (all requests): Will not be used in combination with voclosporin (Lupkynis).

## **PART B PREREQUISITE**



N/A

## **BESREMI**

---

### **MEDICATION(S)**

BESREMI

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

One of the following was ineffective or not tolerated: A) hydroxyurea OR B) peginterferon alfa-2a.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# **BOSULIF**

---

## **MEDICATION(S)**

BOSULIF

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **BRAFTOVI**

---

## **MEDICATION(S)**

BRAFTOVI

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of appropriate BRAF V600E or V600K mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **BRONCHITOL**

---

## **MEDICATION(S)**

BRONCHITOL, BRONCHITOL TOLERANCE TEST

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **BRUKINSA**

---

## **MEDICATION(S)**

BRUKINSA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **CABOMETYX**

---

## **MEDICATION(S)**

CABOMETYX

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **CALQUENCE**

---

### **MEDICATION(S)**

CALQUENCE

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A



# CAPLYTA

---

## **MEDICATION(S)**

CAPLYTA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For schizophrenia: Two of the following were ineffective or not tolerated: a) aripiprazole, b) olanzapine, c) quetiapine, d) risperidone, e) ziprasidone, OR f) lurasidone. For bipolar depression: Both of the following were ineffective or not tolerated: a) lurasidone AND b) quetiapine.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **CAPRELSA**

---

## **MEDICATION(S)**

CAPRELSA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# CARBAGLU

---

## **MEDICATION(S)**

CARGLUMIC ACID

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# CAYSTON

---

## **MEDICATION(S)**

CAYSTON

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## COMETRIQ

---

### **MEDICATION(S)**

COMETRIQ (100 MG DAILY DOSE), COMETRIQ (140 MG DAILY DOSE), COMETRIQ (60 MG DAILY DOSE)

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

## **CONTINUOUS GLUCOSE MONITORS**

---

### **MEDICATION(S)**

DEXCOM G5 MOB/G4 PLAT SENSOR, DEXCOM G5 MOBILE RECEIVER, DEXCOM G5 MOBILE TRANSMITTER, DEXCOM G5 RECEIVER KIT, DEXCOM G6 RECEIVER, DEXCOM G6 SENSOR, DEXCOM G6 TRANSMITTER, DEXCOM G7 RECEIVER, DEXCOM G7 SENSOR, FREESTYLE LIBRE 14 DAY READER, FREESTYLE LIBRE 14 DAY SENSOR, FREESTYLE LIBRE 2 READER, FREESTYLE LIBRE 2 SENSOR, FREESTYLE LIBRE 3 PLUS SENSOR, FREESTYLE LIBRE 3 READER, FREESTYLE LIBRE 3 SENSOR, FREESTYLE LIBRE READER, FREESTYLE LIBRE SENSOR SYSTEM

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 3 years.

### **OTHER CRITERIA**

For Diabetes Mellitus (Initial Requests) - Approve if the member is treated with insulin at least once per day OR has a history of problematic hypoglycemia with documentation of at least one of the following: Recurrent level 2 hypoglycemic events (glucose less than 54mg/dL (3.0mmol/L) that persist despite multiple (2 or more) attempts to adjust medication(s) and/or modify the diabetes treatment plan, or, a history of one level 3 hypoglycemic event (glucose less than 54mg/dL (3.0mmol/L) characterized by

altered mental and/or physical state requiring third-party assistance for treatment of hypoglycemia, AND the member (or the members caregiver) must have been properly trained on using the requested continuous glucose monitor (CGM) as evidenced by the treating practitioner providing a prescription, AND the CGM is prescribed according to its Food and Drug Administration (FDA) indicated use, AND the prescriber has had an in-person visit or approved telehealth visit with the member within the past six months, prior to ordering the CGM, to evaluate their diabetes control. For Diabetes Mellitus (Continuation Requests) - Approve if the treating practitioner conducts an in-person or Medicare-approved telehealth visit with the member to document adherence to their CGM regimen and diabetes treatment plan every six months following the initial prescription of the CGM.

**PART B PREREQUISITE**

N/A

# COPIKTRA

---

## **MEDICATION(S)**

COPIKTRA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A



# COTELLIC

---

## **MEDICATION(S)**

COTELLIC

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For unresectable or metastatic melanoma: Documentation is provided of appropriate BRAF V600E or V600K mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **CYSTARAN**

---

## **MEDICATION(S)**

CYSTARAN

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **CYSTEAMINE**

---

## **MEDICATION(S)**

CYSTAGON

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Concomitant use of Cystagon and Procysbi

## **REQUIRED MEDICAL INFORMATION**

Diagnosis, genetic tests and lab results (as specified in the Other Criteria field)

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Prescribed by or in consultation with a nephrologist or a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases)

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

Cystinosis, nephropathic-approve if the prescriber confirms the diagnosis was confirmed by genetic testing confirming a mutation of the CTNS gene OR white blood cell cystine concentration above the upper limit of the normal reference range for the reporting laboratory.

## **PART B PREREQUISITE**

N/A

# **DALFAMPRIDINE**

---

## **MEDICATION(S)**

DALFAMPRIDINE ER

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

18 years and older (initial and continuation therapy)

## **PRESCRIBER RESTRICTION**

MS - prescribed by or in consultation with a neurologist or MS specialist (initial and continuation).

## **COVERAGE DURATION**

Initial - 4months, Continuation - 1 year.

## **OTHER CRITERIA**

Initial-approve if the patient is ambulatory, the requested medication is being used to improve or maintain mobility in a patient with MS and the patient has impaired ambulation as evaluated by an objective measure (e.g., timed 25 foot walk and multiple sclerosis walking scale-12). Continuation-approve if the patient is ambulatory, the requested medication is being used to improve or maintain mobility in a patient with MS and the patient has responded to or is benefiting from therapy.

## **PART B PREREQUISITE**

N/A

# DARAPRIM

---

## **MEDICATION(S)**

PYRIMETHAMINE 25 MG TAB

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# DAURISMO

---

## MEDICATION(S)

DAURISMO

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# DEFERASIROX

---

## MEDICATION(S)

DEFERASIROX 180 MG TAB, DEFERASIROX 360 MG TAB, DEFERASIROX 90 MG TAB

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

Serum ferritin level

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

Prescribed by or in consultation with a hematologist

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

Transfusion-related chronic iron overload, initial therapy – approve if the patient is receiving blood transfusions at regular intervals for various conditions (eg, thalassemia syndromes, myelodysplastic syndrome, chronic anemia, sickle cell disease) AND prior to starting therapy, the serum ferritin level is greater than 1,000 mcg/L. Non-transfusion-dependent thalassemia syndromes chronic iron overload, initial therapy – approve if prior to starting therapy the serum ferritin level is greater than 300 mcg/L. Continuation therapy – approve if the patient is benefiting from therapy as confirmed by the prescribing physician.

## PART B PREREQUISITE

N/A

# DIACOMIT

---

## **MEDICATION(S)**

DIACOMIT

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Trial of at least one anti-epileptic medication was ineffective or not tolerated.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Prescribed by, or in consultation with, a neurologist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A



# **DRONABINOL**

---

## **MEDICATION(S)**

DRONABINOL

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

Approval will be based off BvD coverage determination.

## **PART B PREREQUISITE**

N/A

# **DUPIXENT**

---

## **MEDICATION(S)**

DUPIXENT

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For initial requests: For atopic dermatitis: Two of the following were ineffective or not tolerated: a) a medium to very high potency topical steroid, b) a topical calcineurin inhibitor OR c) an oral immunosuppressant (trial of other agents not required for patients under 2 years of age). For asthma: History, within the last year of at least 1 asthma exacerbation requiring one of the following, despite regular use of inhaled corticosteroids plus an additional controller(s): a) treatment with systemic corticosteroids, b) emergency department visit OR c) hospitalization. For nasal polyps: Both of the following were ineffective or not tolerated: a) an oral corticosteroid AND b) a nasal corticosteroid. For eosinophilic esophagitis: Trial of topical corticosteroid was ineffective or not tolerated. For prurigo nodularis: Trial of other agents not required. For continuation requests (all diagnoses): Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

For atopic dermatitis: Prescribed by, or in consultation with, an allergist, immunologist, or dermatologist. For asthma: Prescribed by, or in consultation with, an allergist, pulmonologist, or immunologist. For nasal polyps: Prescribed by, or in consultation with, an allergist, immunologist, or otolaryngologist. For eosinophilic esophagitis: Prescribed by, or in consultation with, an allergist or gastroenterologist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

For initial requests: For atopic dermatitis: Member has moderate to severe atopic dermatitis defined as: 1) One of the following: a) body surface area involvement of 10 percent or more OR b) Chart documentation is provided of severity with involvement of the face, head, neck, hands, feet, groin, or intertriginous areas. AND 2) At least two (2) of the following: a) intractable pruritus (itching), b) cracking and oozing/bleeding of skin OR c) impaired activities of daily living. For asthma: One of the following: 1) Eosinophilic phenotype with baseline blood eosinophil concentration greater than or equal to 150 cells/microliter) OR 2) Oral corticosteroid-dependent asthma requiring daily doses of 5 mg or greater prednisone (or equivalent). For nasal polyps, both of the following: A) Bilateral nasal polyposis confirmed with sinus CT scan AND B) Prescriber attests to moderate to severe symptoms of nasal congestion, blockage, or obstruction (such as loss of smell, rhinorrhea, or facial pain). For eosinophilic esophagitis, both of the following: A) endoscopic biopsy with at least 15 eosinophils per high-power field (hpf) AND B) symptoms of esophageal dysfunction (e.g. dysphagia). For prurigo nodularis: Both of the following apply: a) diagnosis has persisted for at least 6 weeks, AND b) at least 20 nodules present at baseline. For all indications (all requests): Will not be used in combination with another targeted immunomodulator product for the prescribed indication.

## **PART B PREREQUISITE**

N/A

# **EMGALITY**

---

## **MEDICATION(S)**

EMGALITY, EMGALITY (300 MG DOSE)

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For migraine initial requests: Both of the following: A) Member has 4 or more migraine days per month for the previous 3 months or longer AND B) An 8-week or greater trial of two of the three following drug classes was ineffective or not tolerated: a) anticonvulsants, b) vasoactive agents, OR c) antidepressants. For episodic cluster headache prophylaxis initial requests: Trial of verapamil was ineffective or not tolerated. For continuation requests (all diagnoses): Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **ENBREL**

---

## **MEDICATION(S)**

ENBREL 25 MG/0.5ML SOLN PRSYR, ENBREL 25 MG/0.5ML SOLUTION, ENBREL 50 MG/ML SOLN PRSYR, ENBREL MINI, ENBREL SURECLICK

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For rheumatoid arthritis (initial requests): Trial of methotrexate at a dose of at least 20mg/week (or maximally tolerated dose) was ineffective or not tolerated. For juvenile idiopathic arthritis (initial requests): Trial of methotrexate at a dose of at least 15 mg/week required (or maximally tolerated dose) was ineffective or not tolerated. For plaque psoriasis (initial requests): One of the following was ineffective or not tolerated: a) methotrexate at a dose of at least 10mg/week (or maximally tolerated dose) OR b) acitretin (trial of other agents not required for patients under 18 years of age). For ankylosing spondylitis (AS)(initial requests): Trial of sulfasalazine was ineffective or not tolerated (Trial of sulfasalazine not required for AS with predominant axial involvement). For psoriatic arthritis (initial requests): One of the following was ineffective or not tolerated: a) methotrexate OR b) sulfasalazine. For juvenile psoriatic arthritis: Trial of other agents not required. For continuation requests (all diagnoses): Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

For rheumatoid arthritis, psoriatic arthritis, juvenile psoriatic arthritis, juvenile idiopathic arthritis or ankylosing spondylitis: Prescribed by, or in consultation with, a rheumatology specialist. For plaque psoriasis: Prescribed by, or in consultation with, a dermatologist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

**OTHER CRITERIA**

N/A

**PART B PREREQUISITE**

N/A

## **ENDARI**

---

### **MEDICATION(S)**

L-GLUTAMINE 5 GM PACKET

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

For initial requests: Criteria 1 and 2 must be met or criteria 3 must be met: 1. Trial of a maximally tolerated hydroxyurea dose was ineffective or not tolerated. 2. Member has had at least 1 vaso-occlusive crisis in the prior 12 months, while on hydroxyurea (if applicable). 3. Prescriber is a hematologist. For continuation requests: Member has benefited with use of this medication.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

Prescribed by, or in consultation with, a hematologist.

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# EPCLUSA

---

## MEDICATION(S)

SOFOSBUVIR-VELPATASVIR

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

1) Current HCV-RNA titer is provided 2) No prior treatment with a direct-acting antiviral for hepatitis C. 3) One of the following: a) Member does not have cirrhosis OR b) Member has compensated cirrhosis AND one of the following: i) Does not have genotype 3 OR ii) has genotype 3 but no NS5A resistance-associated substitution Y93H. OR c) Member has decompensated cirrhosis AND will receive weight-based ribavirin

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

Prescribed by, or in consultation with, a gastroenterologist, hepatologist, or infectious disease or transplant specialist.

## COVERAGE DURATION

Coverage duration of 12 to 24 weeks. Applied consistent with current AASLD-IDSA guidance.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A



# **EPIDIOLEX**

---

## **MEDICATION(S)**

EPIDIOLEX

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Trial of at least one anti-epileptic medication was ineffective or not tolerated.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Prescribed by, or in consultation with, a neurologist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **ERIVEDGE**

---

### **MEDICATION(S)**

ERIVEDGE

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

## **ERLEADA**

---

### **MEDICATION(S)**

ERLEADA

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

For metastatic castration-sensitive prostate cancer: Trial of abiraterone was ineffective or not tolerated.  
For nonmetastatic castration-resistant prostate cancer: Trial of other agents not required.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# **ESBRIET**

---

## **MEDICATION(S)**

PIRFENIDONE 267 MG CAP, PIRFENIDONE 267 MG TAB, PIRFENIDONE 801 MG TAB

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For idiopathic pulmonary fibrosis initial requests: Diagnosis confirmed by one of the following: 1) Surgical lung biopsy revealing histopathological pattern of unspecified interstitial pneumonia (UIP) 2) High-resolution computed tomography indicates definite UIP pattern 3) Both High-resolution computed tomography indicates possible UIP pattern AND surgical lung biopsy reveals a histopathological pattern of probable UIP. For continuation requests: Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **EXKIVITY**

---

### **MEDICATION(S)**

EXKIVITY

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Documentation is provided of EGFR exon 20 insertion mutation.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# **FANAPT**

---

## **MEDICATION(S)**

FANAPT, FANAPT TITRATION PACK

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Two of the following were ineffective or not tolerated: a) aripiprazole, b) olanzapine, c) quetiapine, d) risperidone, e) ziprasidone, OR f) lurasidone.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **FASENRA**

---

## **MEDICATION(S)**

FASENRA, FASENRA PEN

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For initial requests: History within the last year of at least 1 asthma exacerbation requiring one of following, despite regular use of inhaled corticosteroids plus an additional controller(s): a) treatment with systemic corticosteroids, b) emergency department visit OR c) hospitalization. For continuation requests: Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

For asthma: Prescribed by, or in consultation with, an allergist, immunologist, or pulmonologist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

For asthma (initial requests): Eosinophilic phenotype with baseline blood eosinophil concentration greater than or equal to 150 cells/microliter. For asthma (all requests): Will not be used in combination with another targeted immunomodulator product for the prescribed indication.

## **PART B PREREQUISITE**

N/A

# FINTEPLA

---

## **MEDICATION(S)**

FINTEPLA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Trial of at least one anti-epileptic medication was ineffective or not tolerated.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Prescribed by a neurologist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A



## **FIRDAPSE**

---

### **MEDICATION(S)**

FIRDAPSE

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

Prescribed by a neurologist.

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

Diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) confirmed by one of the following: a) Presence of voltage-gated calcium channel antibodies OR b) electrophysiologic compound muscle action potential test findings are consistent with LEMS.

### **PART B PREREQUISITE**

N/A

## **FIRMAGON**

---

### **MEDICATION(S)**

FIRMAGON, FIRMAGON (240 MG DOSE)

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# **FOTIVDA**

---

## **MEDICATION(S)**

FOTIVDA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# FRUZAQLA

---

## **MEDICATION(S)**

FRUZAQLA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **FYCOMPA**

---

## **MEDICATION(S)**

FYCOMPA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For partial-onset seizures: Both of the following were ineffective or not tolerated: a) topiramate AND b) lacosamide. For primary generalized tonic-clonic seizures: Two of the following were ineffective or not tolerated: a) lamotrigine, b) levetiracetam, c) primidone OR d) topiramate.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Prescribed by, or in consultation with, a neurologist or epilepsy specialist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **GAVRETO**

---

## **MEDICATION(S)**

GAVRETO

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of RET gene fusion.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# GILOTRIF

---

## MEDICATION(S)

GILOTRIF

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

Documentation is provided of appropriate EGFR mutation. For squamous non-small cell lung cancer: Documentation of EGFR mutation not required.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

## **GLP-1\_AGONISTS**

---

### **MEDICATION(S)**

BYDUREON BCISE, TRULICITY

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

Continuation - Approve if member has been using the requested medication within the past 180 days.

### **PART B PREREQUISITE**

N/A



## **GROWTH HORMONES NP**

---

### **MEDICATION(S)**

SKYTROFA

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Documentation is provided of failure to stimulate growth hormone secretion (peak growth hormone level of 10mcg/L or less) by one of the acceptable provocative tests.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

## **GROWTH HORMONES**

---

### **MEDICATION(S)**

OMNITROPE

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Documentation is provided of failure to stimulate growth hormone secretion (peak growth hormone level of 10mcg/L or less) by one of the acceptable provocative tests.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

## **HADLIMA**

---

### **MEDICATION(S)**

HADLIMA, HADLIMA PUSHTOUCH

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

For rheumatoid arthritis (initial requests): Trial of methotrexate at a dose of at least 20mg/week (or maximally tolerated dose) was ineffective or not tolerated. For juvenile idiopathic arthritis (initial requests): Trial of methotrexate at a dose of at least 15 mg/week (or maximally tolerated dose) was ineffective or not tolerated. For plaque psoriasis (initial requests): One of the following was ineffective or not tolerated: a) methotrexate at a dose of at least 10mg/week (or maximally tolerated dose) OR b) acitretin. For ankylosing spondylitis (AS)(initial requests): Trial of sulfasalazine was ineffective or not tolerated (Trial of sulfasalazine not required for AS with predominant axial involvement). For psoriatic arthritis (initial requests): One of the following was ineffective or not tolerated: a) methotrexate OR b) sulfasalazine. For ulcerative colitis or Crohn's disease (all requests): Trial of other agents not required. For hidradenitis suppurativa (initial requests): Member must have both of the following: a) At least 3 cysts AND b) Trial of one oral antibiotic was ineffective or not tolerated. For uveitis (initial requests): Both of the following were ineffective or not tolerated: a) a corticosteroid AND b) an immunosuppressant (methotrexate or cyclosporine). For continuation requests (all diagnoses): Member has benefited with use of this medication.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

For rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis or ankylosing spondylitis: Prescribed by, or in consultation with, a rheumatology specialist. For plaque psoriasis and hidradenitis suppurativa: Prescribed by, or in consultation with, a dermatologist. For Crohn's disease and ulcerative colitis: Prescribed by, or in consultation with, a gastroenterologist. For uveitis: Prescribed by, or in

consult with, a rheumatology specialist OR ophthalmologist.

**COVERAGE DURATION**

Approved for duration of 1 year.

**OTHER CRITERIA**

N/A

**PART B PREREQUISITE**

N/A

## **HAE AGENTS**

---

### **MEDICATION(S)**

CINRYZE, HAEGARDA, ICATIBANT ACETATE, RUCONEST, SAJAZIR

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# HARVONI

---

## **MEDICATION(S)**

LEDIPASVIR-SOFOSBUVIR

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

1) Genotype is provided 2) Current HCV-RNA titer is provided 3) Member does or does not have cirrhosis. 4) No prior treatment with a direct-acting antiviral for hepatitis C. 5) Member is intolerant to, or unable to use both of the following: a) Mavyret AND b) Epclusa.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Prescribed by, or in consultation with, a gastroenterologist, hepatologist, infectious disease or transplant specialist.

## **COVERAGE DURATION**

Coverage duration of 12 to 24 weeks. Applied consistent with current AASLD-IDSA guidance.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# HETLIOZ

---

## **MEDICATION(S)**

HETLIOZ, TASIMELTEON

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For non-24-hour sleep-wake disorder: Member is totally blind. For Smith-Magenis syndrome: Diagnosis of nighttime sleep disturbances in Smith-Magenis syndrome.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Prescribed by, or in consultation with, a neurologist or sleep specialist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **HRM\_BENZODIAZEPINES**

---

### **MEDICATION(S)**

ALPRAZOLAM 0.25 MG TAB, ALPRAZOLAM 0.5 MG TAB, ALPRAZOLAM 1 MG TAB, ALPRAZOLAM 2 MG TAB, CLONAZEPAM 0.125 MG TAB DISP, CLONAZEPAM 0.25 MG TAB DISP, CLONAZEPAM 0.5 MG TAB, CLONAZEPAM 0.5 MG TAB DISP, CLONAZEPAM 1 MG TAB, CLONAZEPAM 1 MG TAB DISP, CLONAZEPAM 2 MG TAB, CLONAZEPAM 2 MG TAB DISP, CLONAZEPAM DIPOSSASSIUM, DIAZEPAM 10 MG TAB, DIAZEPAM 2 MG TAB, DIAZEPAM 5 MG TAB, DIAZEPAM 5 MG/5ML SOLUTION, DIAZEPAM 5 MG/ML CONC, DIAZEPAM INTENSOL, LORAZEPAM 0.5 MG TAB, LORAZEPAM 1 MG TAB, LORAZEPAM 2 MG TAB, LORAZEPAM 2 MG/ML CONC, LORAZEPAM INTENSOL, OXAZEPAM, TEMAZEPAM 15 MG CAP, TEMAZEPAM 30 MG CAP

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Procedure-related sedation - 1 month. All other conditions - 12 months.

### **OTHER CRITERIA**

Insomnia - Approve lorazepam, temazepam, or oxazepam if the patient has had a trial with two of the following: ramelteon, trazodone, doxepin 3mg or 6 mg. Prior to approval, the physician must have assessed risk versus benefit for the patient and must confirm that they would still like to initiate/continue therapy. All medically accepted indications other than insomnia - Approve.



**PART B PREREQUISITE**

N/A

# HUMIRA

---

## MEDICATION(S)

HUMIRA (2 PEN) 40 MG/0.8ML PEN KIT, HUMIRA (2 SYRINGE), HUMIRA 10 MG/0.1ML PEF SY KT (ABBVIE), HUMIRA 20 MG/0.2ML PEF SY KT (ABBVIE), HUMIRA 40 MG/0.4ML PEF SY KT (ABBVIE), HUMIRA PEN 40 MG/0.4ML PEN KIT (ABBVIE), HUMIRA PEN 80 MG/0.8ML PEN KIT (ABBVIE), HUMIRA PEN-CD/UC/HS STARTER 80 MG/0.8ML PEN KIT (ABBVIE), HUMIRA PEN-PEDIATRIC UC START 80 MG/0.8ML PEN KIT (ABBVIE), HUMIRA PEN-PSOR/UEIT STARTER, HUMIRA-CD/UC/HS STARTER, HUMIRA-PED<40KG CROHNS STARTER, HUMIRA-PED>=40KG CROHNS START, HUMIRA-PS/UV/ADOL HS STARTER

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

For rheumatoid arthritis (initial requests): Trial of methotrexate at a dose of at least 20mg/week (or maximally tolerated dose) was ineffective or not tolerated. For juvenile idiopathic arthritis (initial requests): Trial of methotrexate at a dose of at least 15 mg/week (or maximally tolerated dose) was ineffective or not tolerated. For plaque psoriasis (initial requests): One of the following was ineffective or not tolerated: a) methotrexate at a dose of at least 10mg/week (or maximally tolerated dose) OR b) acitretin. For ankylosing spondylitis (AS)(initial requests): Trial of sulfasalazine was ineffective or not tolerated (Trial of sulfasalazine not required for AS with predominant axial involvement). For psoriatic arthritis (initial requests): One of the following was ineffective or not tolerated: a) methotrexate OR b) sulfasalazine. For ulcerative colitis or Crohn's disease (all requests): Trial of other agents not required. For hidradenitis suppurativa (initial requests): Member must have both of the following: a) At least 3 cysts AND b) Trial of one oral antibiotic was ineffective or not tolerated. For uveitis (initial requests): Both of the following were ineffective or not tolerated: a) a corticosteroid AND b) an immunosuppressant (methotrexate or cyclosporine). For continuation requests (all diagnoses): Member has benefited with use of this medication.

## AGE RESTRICTION

N/A

**PRESCRIBER RESTRICTION**

For rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis or ankylosing spondylitis: Prescribed by, or in consultation with, a rheumatology specialist. For plaque psoriasis and hidradenitis suppurativa: Prescribed by, or in consultation with, a dermatologist. For Crohn's disease and ulcerative colitis: Prescribed by, or in consultation with, a gastroenterologist. For uveitis: Prescribed by, or in consult with, a rheumatology specialist OR ophthalmologist.

**COVERAGE DURATION**

Approved for duration of 1 year.

**OTHER CRITERIA**

N/A

**PART B PREREQUISITE**

N/A

# **IBRANCE**

---

## **MEDICATION(S)**

IBRANCE

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Intolerance or contraindication to therapy with both of the following: a) Verzenio AND b) Kisqali.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# ICLUSIG

---

## **MEDICATION(S)**

ICLUSIG

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **IDHIFA**

---

### **MEDICATION(S)**

IDHIFA

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Documentation is provided of IDH2 mutation.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# IMATINIB

---

## MEDICATION(S)

IMATINIB MESYLATE

## PA INDICATION INDICATOR

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

## OFF LABEL USES

Chordoma, advanced, aggressive or unresectable fibromatosis (desmoid tumors), cKit positive advanced/recurrent or metastatic melanoma, Kaposi's Sarcoma and pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor, myeloid/lymphoid neoplasms with eosinophilia.

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

Diagnosis. For indications of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported.

## AGE RESTRICTION

ASM, DFSP, HES, MDS/MPD/Myeloid/Lymphoid Neoplasms-18 years and older

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

For ALL/CML, must have Ph-positive for approval of imatinib. Kaposi's Sarcoma-approve if the patient has tried at least one regimen AND has relapsed or refractory disease. Pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)-patient has tried Turalio or according to the prescriber, the patient cannot take Turalio. Myelodysplastic/myeloproliferative disease-approve if the condition is associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements. Graft versus host disease, chronic-approve if the patient has tried at least one conventional systemic treatment (e.g., imbruvica). Metastatic melanoma-approve if the patient has c-Kit-positive advanced/recurrent or metastatic melanoma. Myeloid/lymphoid neoplasms with

eosinophilia-approve if the tumor has an ABL1 rearrangement or an FIP1L1-PDGFRB or PDGFRB rearrangement.

**PART B PREREQUISITE**

N/A



# IMBRUVICA

---

## **MEDICATION(S)**

IMBRUVICA 140 MG CAP, IMBRUVICA 280 MG TAB, IMBRUVICA 420 MG TAB, IMBRUVICA 70 MG CAP, IMBRUVICA 70 MG/ML SUSPENSION

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **INCRELEX**

---

## **MEDICATION(S)**

INCRELEX

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# INGREZZA

---

## MEDICATION(S)

INGREZZA

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

For tardive dyskinesia (initial requests): A) One of the following: i) Member has failed to respond to a change in current antidopaminergic therapy OR ii) Member is unable to switch current antidopaminergic therapy OR iii) Member has symptoms of tardive dyskinesia and is not using antidopaminergic therapy AND B) Member has a functional disability due to tardive dyskinesia. For chorea associated with Huntington's disease (initial requests): Trial of other agents not required. For continuation requests (all diagnoses): Member has benefited with use of this medication.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

Prescribed by, or in consultation with, a neurologist or psychiatrist.

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# INLYTA

---

## MEDICATION(S)

INLYTA

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# **INQOVI**

---

## **MEDICATION(S)**

INQOVI

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **INREBIC**

---

### **MEDICATION(S)**

INREBIC

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Trial of Jakafi was ineffective or not tolerated.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# **IRESSA**

---

## **MEDICATION(S)**

GEFITINIB

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of appropriate EGFR mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **ITRACONAZOLE**

---

## **MEDICATION(S)**

ITRACONAZOLE 10 MG/ML SOLUTION, ITRACONAZOLE 100 MG CAP

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for 6 months.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A



## **IVIG**

---

### **MEDICATION(S)**

GAMMAKED 1 GM/10ML SOLUTION, GAMUNEX-C 1 GM/10ML SOLUTION, HYQVIA, PRIVIGEN 20 GM/200ML SOLUTION

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

Approval will be based off BvD coverage determination.

### **PART B PREREQUISITE**

N/A

# IWILFIN

---

## MEDICATION(S)

IWILFIN

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# JAKAFI

---

## **MEDICATION(S)**

JAKAFI

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# JAYPIRCA

---

## **MEDICATION(S)**

JAYPIRCA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **KALYDECO**

---

## **MEDICATION(S)**

KALYDECO 13.4 MG PACKET, KALYDECO 25 MG PACKET, KALYDECO 5.8 MG PACKET, KALYDECO 50 MG PACKET, KALYDECO 75 MG PACKET

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# KERENDIA

---

## MEDICATION(S)

KERENDIA

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# KEVZARA

---

## MEDICATION(S)

KEVZARA

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

For rheumatoid arthritis (initial requests): Two of the following were ineffective or not tolerated: a) Humira or Hadlima, b) Enbrel, c) Rinvoq OR d) Xeljanz. For polymyalgia rheumatica (initial requests), one of the following: a) a trial of a corticosteroid was ineffective OR b) member was unable to tolerate a corticosteroid taper to less than or equal to 5 mg prednisone equivalent per day. For polyarticular juvenile idiopathic arthritis (initial requests): Two of the following were ineffective or not tolerated: a) Humira or Hadlima, b) Enbrel, c) Xeljanz, d) Rinvoq. For continuation requests (all diagnoses): Member has benefited with use of this medication.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

For rheumatoid arthritis, polymyalgia rheumatica, and polyarticular juvenile idiopathic arthritis: Prescribed by, or in consultation with, a rheumatology specialist.

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A





# KISQALI

---

## MEDICATION(S)

KISQALI (200 MG DOSE), KISQALI (400 MG DOSE), KISQALI (600 MG DOSE), KISQALI FEMARA (200 MG DOSE), KISQALI FEMARA (400 MG DOSE), KISQALI FEMARA (600 MG DOSE)

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# KORLYM

---

## **MEDICATION(S)**

KORLYM, MIFEPRISTONE 300 MG TAB

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **KOSELUGO**

---

## **MEDICATION(S)**

KOSELUGO

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Chart notes documentation is provided that indicates inoperable and symptomatic disease

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# KRAZATI

---

## **MEDICATION(S)**

KRAZATI

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of KRAS G12C mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# KUVAN

---

## **MEDICATION(S)**

SAPROPTERIN DIHYDROCHLORIDE 100 MG PACKET, SAPROPTERIN DIHYDROCHLORIDE 500 MG PACKET

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For continuation therapy: Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Prescribed by, or in consultation with, a medical geneticist or metabolic physician.

## **COVERAGE DURATION**

Initial approval of 3 months. Continuing therapy approved for 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# LENVIMA

---

## MEDICATION(S)

LENVIMA (10 MG DAILY DOSE), LENVIMA (12 MG DAILY DOSE), LENVIMA (14 MG DAILY DOSE), LENVIMA (18 MG DAILY DOSE), LENVIMA (20 MG DAILY DOSE), LENVIMA (24 MG DAILY DOSE), LENVIMA (4 MG DAILY DOSE), LENVIMA (8 MG DAILY DOSE)

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# LETAIRIS

---

## **MEDICATION(S)**

AMBRISENTAN

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Diagnosis confirmed by right heart catheterization.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **LIBERVANT**

---

## **MEDICATION(S)**

LIBERVANT

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A



## **LIDOCAINE\_PATCH**

---

### **MEDICATION(S)**

LIDOCAINE PATCHES

### **PA INDICATION INDICATOR**

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

### **OFF LABEL USES**

Diabetic neuropathic pain, chronic back pain

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# **LONG ACTING OPIOIDS**

---

## **MEDICATION(S)**

BELBUCA, BUPRENORPHINE 10 MCG/HR PATCH WK, BUPRENORPHINE 15 MCG/HR PATCH WK, BUPRENORPHINE 20 MCG/HR PATCH WK, BUPRENORPHINE 5 MCG/HR PATCH WK, BUPRENORPHINE 7.5 MCG/HR PATCH WK, METHADONE HCL 10 MG TAB, METHADONE HCL 5 MG TAB, METHADONE HCL 10 MG/5ML SOLUTION, METHADONE HCL 5 MG/5ML SOLUTION, MORPHINE SULFATE ER 100 MG TAB ER, MORPHINE SULFATE ER 15 MG TAB ER, MORPHINE SULFATE ER 200 MG TAB ER, MORPHINE SULFATE ER 30 MG TAB ER, MORPHINE SULFATE ER 60 MG TAB ER

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

Acute (ie, non-chronic) pain

## **REQUIRED MEDICAL INFORMATION**

Pain type (chronic vs acute), prior pain medications/therapies tried, concurrent pain medications/therapies

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

'For pain severe enough to require daily, around-the-clock, long-term opioid treatment, approve if all of the following criteria are met: 1) patient is not opioid naive, AND 2) non-opioid therapies have been tried and are being used in conjunction with opioid therapy according to the prescribing physician, AND 3) the prescribing physician has checked the patient's history of controlled substance prescriptions

using state prescription drug monitoring program (PDMP), AND 4) the prescribing physician has discussed risks (eg, addiction, overdose) and realistic benefits of opioid therapy with the patient, AND 5) according to the prescriber physician there is a treatment plan (including goals for pain and function) in place and reassessments are scheduled at regular intervals. Patients with cancer, in hospice, sickle cell disease or who reside in a long term care facility are not required to meet above criteria. Clinical criteria incorporated into the quantity limit edits for all oral long-acting opioids require confirmation that the indication is intractable pain (ie, FDA labeled use) prior to reviewing for quantity exception.

**PART B PREREQUISITE**

N/A

# **LONSURF**

---

## **MEDICATION(S)**

LONSURF

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# LORBRENA

---

## **MEDICATION(S)**

LORBRENA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of ALK-positive disease.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# LUMAKRAS

---

## **MEDICATION(S)**

LUMAKRAS

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of KRAS G12C mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# LYNPARZA

---

## **MEDICATION(S)**

LYNPARZA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# LYTGOBI

---

## **MEDICATION(S)**

LYTGOBI (12 MG DAILY DOSE), LYTGOBI (16 MG DAILY DOSE), LYTGOBI (20 MG DAILY DOSE)

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of FGFR2 fusion or other rearrangement

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A



# MAVYRET

---

## MEDICATION(S)

MAVYRET

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

1) Current HCV-RNA titer is provided 2) Member does not have decompensated cirrhosis 3) One of the following: a) no prior treatment with a direct-acting antiviral for hepatitis C, OR b) prior treatment with sofosbuvir-based regimen and all of the following: i) Member does not have genotype 3 AND ii) No prior treatment with an NS3/4A protease inhibitor.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

Prescribed by, or in consultation with, a gastroenterologist, hepatologist, or infectious disease or transplant specialist.

## COVERAGE DURATION

Coverage duration of 8 to 16 weeks. Applied consistent with current AASLD-IDSA guidance.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

## **MEGESTROL SUSP**

---

### **MEDICATION(S)**

MEGESTROL ACETATE 40 MG/ML SUSPENSION, MEGESTROL ACETATE 400 MG/10ML SUSPENSION, MEGESTROL ACETATE 625 MG/5ML SUSPENSION, MEGESTROL ACETATE 800 MG/20ML SUSPENSION

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

## **MEGESTROL TABS**

---

### **MEDICATION(S)**

MEGESTROL ACETATE 20 MG TAB, MEGESTROL ACETATE 40 MG TAB

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# **MEKINIST**

---

## **MEDICATION(S)**

MEKINIST

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of appropriate BRAF V600E or V600K mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **MEKTOVI**

---

### **MEDICATION(S)**

MEKTOVI

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Documentation is provided of appropriate BRAF V600E or V600K mutation.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# **MIGRANAL**

---

## **MEDICATION(S)**

DIHYDROERGOTAMINE MESYLATE 4 MG/ML SOLUTION

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Trial of two different triptans was ineffective or not tolerated.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **MODAFINIL\_ARMODAFINIL**

---

### **MEDICATION(S)**

ARMODAFINIL, MODAFINIL 100 MG TAB, MODAFINIL 200 MG TAB

### **PA INDICATION INDICATOR**

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

### **OFF LABEL USES**

Excessive daytime sleepiness (EDS) associated with myotonic dystrophy - modafinil only.

Adjunctive/augmentation for treatment of depression in adults - modafinil only. Fatigue due to multiple sclerosis - modafinil only. Idiopathic hypersomnia - modafinil only.

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

### **AGE RESTRICTION**

Fatigue due to MS and Idiopathic hypersomnia - 18 years of age and older. All others - 17 years of age and older.

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Authorization will be for 12 months.

### **OTHER CRITERIA**

Excessive daytime sleepiness associated with Shift Work Sleep Disorder (SWSD) - Approve if the patient is working at least 5 overnight shifts per month. Adjunctive/augmentation treatment for depression in adults - Approve if the patient is concurrently receiving other medication therapy for depression. Excessive daytime sleepiness associated with obstructive sleep apnea/hypoapnea syndrome - Approve. Excessive daytime sleepiness associated with Narcolepsy - Approve if narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). Fatigue due to multiple sclerosis - Approve. Idiopathic hypersomnia - Approve.

**PART B PREREQUISITE**

N/A



## **MS\_AGENTS**

---

### **MEDICATION(S)**

AVONEX PEN, AVONEX PREFILLED, DIMETHYL FUMARATE 120 MG CAP DR, DIMETHYL FUMARATE 240 MG CAP DR, DIMETHYL FUMARATE STARTER PACK, FINGOLIMOD HCL, GLATIRAMER ACETATE, GLATOPA, KESIMPTA, PLEGRIDY, TERIFLUNOMIDE

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Diagnosis. For Avonex, Kesimpta, Plegridy: must first try one of teriflunomide, dimethyl fumarate, fingolimod, or glatiramer acetate.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# NERLYNX

---

## MEDICATION(S)

NERLYNX

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# **NEXAVAR**

---

## **MEDICATION(S)**

SORAFENIB TOSYLATE

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **NEXVIAZYME**

---

## **MEDICATION(S)**

NEXVIAZYME

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Diagnosis

## **AGE RESTRICTION**

1 year and older

## **PRESCRIBER RESTRICTION**

Prescribed by or in consultation with a geneticist, neurologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.

## **COVERAGE DURATION**

1 year

## **OTHER CRITERIA**

Acid alpha-glucosidase deficiency (Pompe Disease)-approve if the patient has late-onset acid alpha-glucosidase deficiency (late-onset Pompe Disease) and the diagnosis is established by laboratory test demonstrating deficient acid alpha-glucosidase activity in the blood, fibroblasts or muscle tissue or patient has a molecular genetic test demonstrating acid alpha-glucosidase gene mutation.

## **PART B PREREQUISITE**

N/A

# **NILUTAMIDE**

---

## **MEDICATION(S)**

NILUTAMIDE

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Diagnosis

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

Prostate cancer-approve if nilutamide is used concurrently with a luteinizing hormone-releasing hormone (LHRH) agonist.

## **PART B PREREQUISITE**

N/A

## **NINLARO**

---

### **MEDICATION(S)**

NINLARO

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

## **NORTHERA**

---

### **MEDICATION(S)**

DROXIDOPA

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# **NOURIANZ**

---

## **MEDICATION(S)**

NOURIANZ

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

One agent from both of the following classes was ineffective or not tolerated: a) COMT inhibitor AND b) MAO-B inhibitor.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A



# **NOXAFIL**

---

## **MEDICATION(S)**

POSACONAZOLE 100 MG TAB DR

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **NUBEQA**

---

### **MEDICATION(S)**

NUBEQA

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

For metastatic hormone-sensitive prostate cancer: Trial of abiraterone was ineffective or not tolerated.

For non-metastatic castration-resistant prostate cancer: Trial of other agents not required.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# **NUEDEXTA**

---

## **MEDICATION(S)**

NUEDEXTA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For initial requests: A) Documentation is provided (in the form of chart notes or imaging) of structural neurological condition as the cause of pseudobulbar affect. For continuation requests, both of the following: A) Documentation is provided (in the form of chart notes or imaging) of structural neurological condition as the cause of pseudobulbar affect AND B) Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **NUPLAZID**

---

## **MEDICATION(S)**

NUPLAZID

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **NURTEC**

---

## **MEDICATION(S)**

NURTEC

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Migraine, acute treatment – Pt has tried at least one triptan therapy or has a contraindication to triptans according to the prescriber. Preventive treatment of episodic migraine - Both of the following: A) Member has 4 or more migraine days per month for the previous 3 months or longer AND B) An 8-week or greater trial of two of the three following drug classes was ineffective or not tolerated: a) anticonvulsants, b) vasoactive agents, OR c) antidepressants OR the member has already tried an oral or injectable calcitonin gene-related peptide (CGRP) inhibitor indicated for the prevention of migraine or Botox (onabotulinumtoxinA injection) for the prevention of migraines. For continuation requests: Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A



## **OCTREOTIDE**

---

### **MEDICATION(S)**

OCTREOTIDE ACETATE 100 MCG/ML SOLUTION, OCTREOTIDE ACETATE 1000 MCG/ML SOLUTION, OCTREOTIDE ACETATE 200 MCG/ML SOLUTION, OCTREOTIDE ACETATE 50 MCG/ML SOLUTION, OCTREOTIDE ACETATE 500 MCG/ML SOLUTION

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# **ODOMZO**

---

## **MEDICATION(S)**

ODOMZO

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A



## **OFEV**

---

### **MEDICATION(S)**

OFEV

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

1) For idiopathic pulmonary fibrosis initial requests: A) Diagnosis confirmed by one of the following: i) Surgical lung biopsy revealing histopathological pattern of unspecified interstitial pneumonia (UIP) ii) High-resolution computed tomography (HRCT) indicates definite UIP pattern iii) Both HRCT indicates possible UIP pattern AND surgical lung biopsy reveals a histopathological pattern of probable UIP AND B) Trial of pirfenidone was ineffective or not tolerated. 2) For systemic sclerosis-associated interstitial lung disease (ILD) initial requests: A) Diagnosis confirmed with documentation provided of both of the following: i) HRCT scan AND ii) pulmonary function tests AND B) Trial of mycophenolate mofetil was ineffective or not tolerated. 3) For chronic fibrosing ILDs with a progressive phenotype initial requests: A) Disease is progressive, defined by one of the following over the past 12 months, with no alternative explanation: i) worsening respiratory symptoms, ii) one of the following: a) forced vital capacity (FVC) decline of 5% or more OR b) corrected hemoglobin decline of 10% or more OR iii) radiological evidence of disease progression AND B) Progression occurred despite treatment with one of the following: i) azathioprine ii) cyclosporine iii) mycophenolate mofetil iv) tacrolimus v) oral corticosteroids equivalent to 20 mg or more per day of prednisone vi) cyclophosphamide vii) rituximab. 4) For continuation requests (all diagnoses): Member has benefited with use of this medication.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

**OTHER CRITERIA**

N/A

**PART B PREREQUISITE**

N/A

# **OGSIVEO**

---

## **MEDICATION(S)**

OGSIVEO

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **OJEMDA**

---

### **MEDICATION(S)**

OJEMDA

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# OJJAARA

---

## **MEDICATION(S)**

OJJAARA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **ONUREG**

---

### **MEDICATION(S)**

ONUREG

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

## **OPSUMIT**

---

### **MEDICATION(S)**

OPSUMIT

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Diagnosis confirmed by right heart catheterization.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

## **ORFADIN**

---

### **MEDICATION(S)**

NITISINONE

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A



# ORGOVYX

---

## **MEDICATION(S)**

ORGOVYX

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# ORKAMBI

---

## MEDICATION(S)

ORKAMBI

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

## **ORSERDU**

---

### **MEDICATION(S)**

ORSERDU

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Documentation is provided of ESR1 mutation.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# OTEZLA

---

## MEDICATION(S)

OTEZLA 10 & 20 & 30 MG TAB THPK, OTEZLA 30 MG TAB

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

For oral ulcers associated with Behcet's disease (initial requests): Trial of topical triamcinolone 0.1% oral paste was ineffective or not tolerated. For psoriatic arthritis (initial requests): One of the following was ineffective or not tolerated: a) methotrexate OR b) sulfasalazine. For plaque psoriasis (initial requests): One of the following was ineffective or not tolerated: a) methotrexate at a dose of 10mg/week (or maximally tolerated dose) OR b) acitretin (trial of other agents not required for patients under 18 years of age). For continuation requests (all diagnoses): Member has benefited with use of this medication.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

For oral ulcers associated with Behcet's disease and psoriatic arthritis: Prescribed by, or in consultation with, a rheumatology specialist. For Plaque Psoriasis: Prescribed by, or in consultation with, a dermatologist.

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

For oral ulcers associated with Behcet's disease (initial requests): Diagnosis confirmed by the presence of oral ulcers AND at least two of the following: recurrent genital ulceration, eye lesions, skin lesions, positive pathergy test. For psoriatic arthritis and plaque psoriasis (all requests): Will not be used in

combination with biologic therapy for the prescribed indication.

**PART B PREREQUISITE**

N/A

# **OXERVATE**

---

## **MEDICATION(S)**

OXERVATE

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Eye to be treated has never been treated with Oxervate in the past.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Prescribed by an ophthalmologist.

## **COVERAGE DURATION**

Approved for 3 months.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# PANRETIN

---

## MEDICATION(S)

PANRETIN

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

## **PART D VS PART B**

---

### **MEDICATION(S)**

ABELCET, ACETYLCYSTEINE 10 % SOLUTION, ACETYLCYSTEINE 20 % SOLUTION, ACYCLOVIR SODIUM, ALBUTEROL SULFATE (2.5 MG/3ML) 0.083% NEBU SOLN, ALBUTEROL SULFATE (5 MG/ML) 0.5% NEBU SOLN, ALBUTEROL SULFATE 0.63 MG/3ML NEBU SOLN, ALBUTEROL SULFATE 1.25 MG/3ML NEBU SOLN, ALBUTEROL SULFATE 2.5 MG/0.5ML NEBU SOLN, AMPHOTERICIN B 50 MG RECON SOLN, APREPITANT, ARFORMOTEROL TARTRATE, AZATHIOPRINE 50 MG TAB, BUDESONIDE 0.25 MG/2ML SUSPENSION, BUDESONIDE 0.5 MG/2ML SUSPENSION, BUDESONIDE 1 MG/2ML SUSPENSION, CLINIMIX/DEXTROSE (4.25/10), CLINIMIX/DEXTROSE (4.25/5), CLINIMIX/DEXTROSE (5/15), CLINIMIX/DEXTROSE (5/20), CROMOLYN SODIUM 20 MG/2ML NEBU SOLN, CYCLOPHOSPHAMIDE 25 MG TAB, CYCLOPHOSPHAMIDE 50 MG TAB, CYCLOPHOSPHAMIDE 25 MG CAP, CYCLOPHOSPHAMIDE 50 MG CAP, CYCLOSPORINE 100 MG CAP, CYCLOSPORINE 25 MG CAP, CYCLOSPORINE MODIFIED, DEXTROSE 10 % SOLUTION, DEXTROSE-SODIUM CHLORIDE 10-0.2 % SOLUTION, DEXTROSE-SODIUM CHLORIDE 10-0.45 % SOLUTION, DIPHTHERIA-TETANUS TOXOIDS DT, ENGERIX-B, ENVARSUS XR, EVEROLIMUS 0.25 MG TAB, EVEROLIMUS 0.5 MG TAB, EVEROLIMUS 0.75 MG TAB, EVEROLIMUS 1 MG TAB, FORMOTEROL FUMARATE 20 MCG/2ML NEBU SOLN, GENGRAF, GRANISETRON HCL 1 MG TAB, HEPLISAV-B, HUMULIN R U-500 (CONCENTRATED), HYDROMORPHONE HCL PF 10 MG/ML SOLUTION, HYDROMORPHONE HCL PF 50 MG/5ML SOLUTION, HYDROMORPHONE HCL PF 500 MG/50ML SOLUTION, IMOVAX RABIES, INSULIN ASPART, IPRATROPIUM BROMIDE 0.02 % SOLUTION, IPRATROPIUM-ALBUTEROL, LEVALBUTEROL HCL 0.31 MG/3ML NEBU SOLN, LEVALBUTEROL HCL 0.63 MG/3ML NEBU SOLN, LEVALBUTEROL HCL 1.25 MG/0.5ML NEBU SOLN, LEVALBUTEROL HCL 1.25 MG/3ML NEBU SOLN, METHYLPREDNISOLONE 16 MG TAB, METHYLPREDNISOLONE 32 MG TAB, METHYLPREDNISOLONE 4 MG TAB, METHYLPREDNISOLONE 8 MG TAB, MYCOPHENOLATE MOFETIL 200 MG/ML RECON SUSP, MYCOPHENOLATE MOFETIL 250 MG CAP, MYCOPHENOLATE MOFETIL 500 MG TAB, MYCOPHENOLATE SODIUM, MYCOPHENOLIC ACID, NOVOLOG, NOVOLOG RELION, ONDANSETRON 4 MG TAB DISP, ONDANSETRON 8 MG TAB DISP, ONDANSETRON HCL 4 MG TAB, ONDANSETRON HCL 4 MG/5ML SOLUTION, ONDANSETRON HCL 8 MG TAB, PENTAMIDINE ISETHIONATE FOR NEBULIZATION SOLUTION, PLENAMINE, PREDNISOLONE 15 MG/5ML SOLUTION, PREDNISOLONE SODIUM PHOSPHATE 15 MG/5ML SOLUTION, PREDNISOLONE SODIUM PHOSPHATE 20 MG/5ML SOLUTION, PREDNISOLONE SODIUM PHOSPHATE 25 MG/5ML SOLUTION, PREDNISOLONE SODIUM PHOSPHATE 6.7 (5 BASE) MG/5ML SOLUTION, PREDNISONONE 1 MG TAB, PREDNISONONE 10 MG TAB, PREDNISONONE 2.5 MG TAB, PREDNISONONE 20 MG TAB, PREDNISONONE 5 MG TAB, PREDNISONONE 5 MG/5ML SOLUTION, PREDNISONONE 50 MG TAB, PREDNISONONE INTENSOL,



PREHEVBRIO, PROGRAF 0.2 MG PACKET, PROGRAF 1 MG PACKET, PULMOZYME, RABAVERT, RECOMBIVAX HB, SIROLIMUS 0.5 MG TAB, SIROLIMUS 1 MG TAB, SIROLIMUS 1 MG/ML SOLUTION, SIROLIMUS 2 MG TAB, TACROLIMUS 0.5 MG CAP, TACROLIMUS 1 MG CAP, TACROLIMUS 5 MG CAP, TDVAX, TENIVAC, TETANUS-DIPHThERIA TOXOIDS TD, VARUBI (180 MG DOSE)

#### **DETAILS**

This drug may be covered under Medicare Part B or D depending on the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

# PEGASYS

---

## **MEDICATION(S)**

PEGASYS

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Diagnosis

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# PEMAZYRE

---

## MEDICATION(S)

PEMAZYRE

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

Documentation is provided of appropriate FGFR fusion or rearrangement.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# **PENICILLAMINE**

---

## **MEDICATION(S)**

PENICILLAMINE 250 MG TAB

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Diagnosis

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Wilson's Disease-Prescribed by or in consultation with a gastroenterologist, hepatologist or liver transplant physician

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **PHENYLBUTYRATE**

---

### **MEDICATION(S)**

SODIUM PHENYLBUTYRATE 500 MG TAB

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Concomitant use of Ravicti and Buphenyl

### **REQUIRED MEDICAL INFORMATION**

Diagnosis, genetic tests and lab results (as specified in the Other Criteria field)

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

Prescribed by or in consultation with a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases)

### **COVERAGE DURATION**

Pt meets criteria with no genetic test - 3 mo approval. Pt had genetic test - 12 mo approval

### **OTHER CRITERIA**

Urea cycle disorders-approve if genetic testing confirmed a mutation resulting in a urea cycle disorder or if the patient has hyperammonemia.

### **PART B PREREQUISITE**

N/A

## **PIQRAY**

---

### **MEDICATION(S)**

PIQRAY (200 MG DAILY DOSE), PIQRAY (250 MG DAILY DOSE), PIQRAY (300 MG DAILY DOSE)

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Documentation is provided of PIK3CA-mutation.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# **POMALYST**

---

## **MEDICATION(S)**

POMALYST

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# PRALUENT

---

## MEDICATION(S)

PRALUENT

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

Trial of Repatha was ineffective or not tolerated.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A



# PROMACTA

---

## MEDICATION(S)

PROMACTA

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# **QINLOCK**

---

## **MEDICATION(S)**

QINLOCK

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# QUININE

---

## **MEDICATION(S)**

QUININE SULFATE 324 MG CAP

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for 1 month.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **RADICAVA**

---

### **MEDICATION(S)**

RADICAVA ORS, RADICAVA ORS STARTER KIT

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

For initial requests: Member has a score of two or greater for each individual item on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R). For continuation requests: Member has benefited with use of this medication.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

Prescribed by, or in consultation with, a neurologist.

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# RELISTOR

---

## MEDICATION(S)

RELISTOR 12 MG/0.6ML SOLUTION, RELISTOR 8 MG/0.4ML SOLUTION

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

For the treatment of opioid-induced constipation (OIC) in adults with advanced illness who are receiving palliative care: Trial of lactulose was ineffective or not tolerated.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for 4 months.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# RELSTONE

---

## MEDICATION(S)

RELSTONE

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

Trial of generic ursodiol 300 mg capsule was ineffective or not tolerated

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# REPATHA

---

## **MEDICATION(S)**

REPATHA, REPATHA PUSHTRONEX SYSTEM, REPATHA SURECLICK

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# RETACRIT

---

## **MEDICATION(S)**

RETACRIT

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A



## **RETEVMO**

---

### **MEDICATION(S)**

RETEVMO

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Documentation is provided of RET mutation or RET gene fusion.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# REVATIO

---

## **MEDICATION(S)**

SILDENAFIL CITRATE 20 MG TAB

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Diagnosis confirmed by right heart catheterization.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **REVLIMID**

---

### **MEDICATION(S)**

LLENALIDOMIDE, REVLIMID

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# REZLIDHIA

---

## **MEDICATION(S)**

REZLIDHIA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of IDH1 mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# REZUROCK

---

## MEDICATION(S)

REZUROCK

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# RILUZOLE

---

## **MEDICATION(S)**

RILUZOLE

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Diagnosis

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of ALS.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# RINVOQ

---

## MEDICATION(S)

RINVOQ

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

For rheumatoid arthritis (initial requests): One of the following was ineffective or not tolerated: a) Humira or Hadlima OR b) Enbrel. For psoriatic arthritis (initial requests): One of the following was ineffective or not tolerated: a) Humira or Hadlima OR b) Enbrel. For atopic dermatitis (initial requests): Two of the following were ineffective or not tolerated: a) a medium to very high potency topical steroid, b) a topical calcineurin inhibitor OR c) an oral immunosuppressant. For ulcerative colitis (initial requests): Trial of Humira or Hadlima was ineffective or not tolerated. For ankylosing spondylitis (initial requests): One of the following was ineffective or not tolerated: a) Humira or Hadlima OR b) Enbrel. For non-radiographic axial spondyloarthritis (initial requests): Trial of Cimzia was ineffective or not tolerated. For Crohn's disease (initial requests): Trial of Humira or Hadlima was ineffective or not tolerated. For juvenile idiopathic arthritis (initial requests): One of the following was ineffective or not tolerated: a) Humira or Hadlima OR b) Enbrel. For continuation requests (all diagnoses): Member has benefited with use of this medication.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

For rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, or juvenile idiopathic arthritis: Prescribed by, or in consultation with, a rheumatology specialist. For atopic dermatitis: Prescribed by, or in consultation with, an allergist, immunologist, or dermatologist. For Crohn's disease or ulcerative colitis: Prescribed by, or in consultation with a gastroenterologist.

**COVERAGE DURATION**

Approved for duration of 1 year.

**OTHER CRITERIA**

For atopic dermatitis (initial requests): Member has moderate to severe atopic dermatitis defined as: 1) One of the following: a) body surface area involvement of 10 percent or more OR b) Chart documentation is provided of severity with involvement of the face, head, neck, hands, feet, groin, or intertriginous areas. AND 2) At least two (2) of the following: a) intractable pruritus (itching), b) cracking and oozing/bleeding of skin OR c) impaired activities of daily living. For atopic dermatitis (all requests): Will not be used in combination with another targeted immunomodulator product for the prescribed indication.

**PART B PREREQUISITE**

N/A



# ROZLYTREK

---

## **MEDICATION(S)**

ROZLYTREK

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided showing one of the following: a) ROS1 rearrangement OR b) NTRK gene fusion mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **RUBRACA**

---

### **MEDICATION(S)**

RUBRACA

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# **RYDAPT**

---

## **MEDICATION(S)**

RYDAPT

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# SABRIL

---

## **MEDICATION(S)**

VIGABATRIN, VIGADRONE, VIGPODER

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **SCEMBLIX**

---

## **MEDICATION(S)**

SCEMBLIX

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For T315I mutation: failure of or intolerance to Iclusig required.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **SECUADO**

---

### **MEDICATION(S)**

SECUADO

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Two of the following were ineffective or not tolerated: a) aripiprazole, b) olanzapine, c) quetiapine, d) risperidone, e) ziprasidone, f) lurasidone, OR g) oral asenapine.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

## **SENSIPAR**

---

### **MEDICATION(S)**

CINACALCET HCL

### **PA INDICATION INDICATOR**

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

### **OFF LABEL USES**

hyperparathyroidism in post-renal transplant patients

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Diagnosis

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

Hypercalcemia d/t parathyroid CA-prescr/consult w/onco or endo. Hypercalcemia w/primary hyperparathyroidism-prescr/consult w/nephro or endo. Hyperparathyroidism in post-renal transplant-prescr/consult w/transplant physician/nephro/endo.

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

Hypercalcemia due to parathyroid carcinoma-approve. Hypercalcemia in patients with primary hyperparathyroidism-approve if the patient has failed or is unable to undergo a parathyroidectomy due to a contraindication. Secondary Hyperparathyroidism in patients with chronic kidney disease on dialysis - deny under Medicare Part D (claim should be submitted under the ESRD bundles payment benefit). Hyperparathyroidism in Post-Renal Transplant Patients-approve if the baseline (prior to starting cinacalcet therapy) calcium and intact parathyroid hormone (iPTH) levels are above the normal range, as defined by the laboratory reference values.

### **PART B PREREQUISITE**

N/A



# **SIGNIFOR**

---

## **MEDICATION(S)**

SIGNIFOR

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **SIMPONI**

---

## **MEDICATION(S)**

SIMPONI

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For rheumatoid arthritis (initial requests): Two of the following were ineffective or not tolerated: a) Humira or Hadlima, b) Enbrel, c) Rinvoq OR d) Xeljanz. For ankylosing spondylitis (initial requests): Two of the following were ineffective or not tolerated: a) Humira or Hadlima, b) Enbrel, c) Taltz d) Rinvoq OR e) Xeljanz. For psoriatic arthritis (initial requests): Two of the following were ineffective or not tolerated: a) Humira or Hadlima, b) Enbrel, c) Taltz, d) Stelara, e) Otezla, f) Skyrizi, g) Tremfya, h) Rinvoq, OR i) Xeljanz. For ulcerative colitis (initial requests): Two of the following were ineffective or not tolerated: a) Humira or Hadlima, b) Stelara, c) Rinvoq, Xeljanz, or e) Skyrizi. For continuation requests (all diagnoses): Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

For rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: Prescribed by, or in consultation with, a rheumatology specialist. For ulcerative colitis : Prescribed by, or in consultation with, a gastroenterologist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

**PART B PREREQUISITE**

N/A

# **SIRTURO**

---

## **MEDICATION(S)**

SIRTURO

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# SIVEXTRO

---

## **MEDICATION(S)**

SIVEXTRO 200 MG TAB

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for 6 months.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# SKYRIZI

---

## MEDICATION(S)

SKYRIZI 150 MG/ML SOLN PRSYR, SKYRIZI 180 MG/1.2ML SOLN CART, SKYRIZI 360 MG/2.4ML SOLN CART, SKYRIZI PEN

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

For plaque psoriasis (initial requests): One of the following was ineffective or not tolerated: a) methotrexate at a dose of at least 10mg/week (or maximally tolerated dose) OR b) acitretin. For psoriatic arthritis (initial requests): One of the following was ineffective or not tolerated: a) methotrexate OR b) sulfasalazine. For Crohn's disease (all requests): Trial of other agents not required. For ulcerative colitis (all requests): Trial of other agents not required. For continuation requests (all diagnoses): Member has benefited with use of this medication.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

For plaque psoriasis: Prescribed by, or in consultation with, a dermatologist. For Psoriatic Arthritis: Prescribed by, or in consultation with, a rheumatology specialist. For Crohn's Disease and ulcerative colitis: Prescribed by, or in consultation with, a gastroenterologist.

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# **SOLARAZE**

---

## **MEDICATION(S)**

DICLOFENAC SODIUM 3 % GEL

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A



# SOMAVERT

---

## MEDICATION(S)

SOMAVERT

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# SPRYCEL

---

## **MEDICATION(S)**

DASATINIB

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# STELARA

---

## MEDICATION(S)

STELARA 45 MG/0.5ML SOLN PRSYR, STELARA 45 MG/0.5ML SOLUTION, STELARA 90 MG/ML SOLN PRSYR

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

For plaque psoriasis (initial requests): One of the following was ineffective or not tolerated: a) methotrexate at a dose of at least 10mg/week (or maximally tolerated dose) OR b) acitretin (trial of other agents not required for patients under 18 years of age). For psoriatic arthritis (initial requests): One of the following was ineffective or not tolerated: a) methotrexate OR b) sulfasalazine. For ulcerative colitis and Crohn's disease (all requests): Trial of other agents not required. For continuation requests (all diagnoses): Member has benefited with use of this medication.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

For psoriatic arthritis: Prescribed by, or in consultation with, a rheumatology specialist. For Crohn's disease and ulcerative colitis: Prescribed by, or in consultation with, a gastroenterologist. For plaque psoriasis: Prescribed by, or in consultation with, a dermatologist.

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# STIVARGA

---

## MEDICATION(S)

STIVARGA

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# SUCRAID

---

## **MEDICATION(S)**

SUCRAID

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# SUNOSI

---

## MEDICATION(S)

SUNOSI

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

One of the following was ineffective or not tolerated: a) modafinil OR b) armodafinil.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

Documentation is provided of full nocturnal polysomnogram used to confirm diagnosis.

## PART B PREREQUISITE

N/A

# SUTENT

---

## MEDICATION(S)

SUNITINIB MALATE

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A



# **SYNRIBO**

---

## **MEDICATION(S)**

SYNRIBO

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **SYPRINE**

---

## **MEDICATION(S)**

TRIENTINE HCL 250 MG CAP

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# TABRECTA

---

## **MEDICATION(S)**

TABRECTA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of MET exon 14 skipping mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# TAFINLAR

---

## MEDICATION(S)

TAFINLAR

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

Documentation is provided of appropriate BRAF V600E or V600K mutation.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# **TAGRISSEO**

---

## **MEDICATION(S)**

TAGRISSEO

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of appropriate EGFR mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# TALTZ

---

## **MEDICATION(S)**

TALTZ 80 MG/ML SOLN A-INJ, TALTZ 80 MG/ML SOLN PRSYR

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For plaque psoriasis (initial requests): One of the following was ineffective or not tolerated: a) methotrexate at a dose of at least 10mg/week (or maximally tolerated dose) OR b) acitretin (trial of other agents not required for patients under 18 years of age). For ankylosing spondylitis (AS)(initial requests): Trial of sulfasalazine was ineffective or not tolerated (Trial of sulfasalazine not required for AS with predominant axial involvement). For psoriatic arthritis (initial requests): One of the following was ineffective or not tolerated: a) methotrexate OR b) sulfasalazine. For non-radiographic axial spondyloarthritis (initial requests): Trial of two non-steroidal anti-inflammatory drugs (NSAIDs) was ineffective or not tolerated. For continuation requests (all diagnoses): Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

For psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis: Prescribed by, or in consultation with, a rheumatology specialist. For plaque psoriasis: Prescribed by, or in consultation with, a dermatologist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

**PART B PREREQUISITE**

N/A

# TALZENNA

---

## **MEDICATION(S)**

TALZENNA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A



# TARCEVA

---

## **MEDICATION(S)**

ERLOTINIB HCL

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of appropriate EGFR mutation. For pancreatic cancer: Documentation of EGFR mutation not required.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# TARGRETIN

---

## **MEDICATION(S)**

BEXAROTENE

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# TASIGNA

---

## **MEDICATION(S)**

TASIGNA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **TAZVERIK**

---

## **MEDICATION(S)**

TAZVERIK

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# TEPMETKO

---

## **MEDICATION(S)**

TEPMETKO

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of MET exon 14 skipping mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **TERIPARATIDE**

---

### **MEDICATION(S)**

TERIPARATIDE, TERIPARATIDE (RECOMBINANT)

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Concomitant use with other medications for osteoporosis

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

High risk for fracture-2 yrs, Not high risk-approve a max of 2 yrs of therapy (total)/lifetime.

### **OTHER CRITERIA**

Treatment of PMO, approve if pt has tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphosphonate administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried an IV bisphosphonate (ibandronate or zoledronic acid), OR pt has severe renal impairment (creatinine clearance less than 35 mL/min) or CKD or pt has had an osteoporotic fracture or fragility fracture. Increase bone mass in men (a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression) with primary or hypogonadal osteoporosis/Treatment of GIO, approve if pt tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the patient cannot swallow or has difficulty swallowing or the patient cannot remain in an upright position

post oral bisphosphonate administration or has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried zoledronic acid (Reclast), OR pt has severe renal impairment (CrCL less than 35 mL/min) or has CKD or has had an osteoporotic fracture or fragility fracture. Patients who have already taken teriparatide for 2 years - approve if the patient is at high risk for fracture.

**PART B PREREQUISITE**

N/A

# TESTOSTERONE

---

## MEDICATION(S)

ERYTHROMYCIN BASE 250 MG CP DR PART, TESTOSTERONE 1.62 % GEL, TESTOSTERONE 10 MG/ACT (2%) GEL, TESTOSTERONE 20.25 MG/1.25GM (1.62%) GEL, TESTOSTERONE 20.25 MG/ACT (1.62%) GEL, TESTOSTERONE 30 MG/ACT SOLUTION, TESTOSTERONE 40.5 MG/2.5GM (1.62%) GEL, TESTOSTERONE 50 MG/5GM (1%) GEL, TESTOSTERONE 25 MG/2.5GM (1%) GEL, TESTOSTERONE 50 MG/5GM (1%) GEL, TESTOSTERONE CYPIONATE 200 MG/ML SOLUTION, TESTOSTERONE CYPIONATE 100 MG/ML SOLUTION, TESTOSTERONE CYPIONATE 200 MG/ML SOLUTION, TESTOSTERONE ENANTHATE 200 MG/ML SOLUTION

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

A) For initial requests: documentation is provided of morning testosterone levels, from two separate days, that fall below the normal range for a healthy adult male. B) For continuation requests: Member has benefited with use of this medication.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE



N/A

# TIBSOVO

---

## **MEDICATION(S)**

TIBSOVO

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of IDH1 mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# TOBI

---

## **MEDICATION(S)**

TOBRAMYCIN 300 MG/4ML NEBU SOLN, TOBRAMYCIN 300 MG/5ML NEBU SOLN

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

Approval will be based off BvD coverage determination.

## **PART B PREREQUISITE**

N/A

# **TOLCAPONE**

---

## **MEDICATION(S)**

TOLCAPONE

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Diagnosis, use of carbidopa/levodopa, and use of entacapone and associated clinical outcome

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Prescribed by or in consultation with a neurologist

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

Parkinson's disease-approve if the patient is currently receiving carbidopa/levodopa therapy and the patient has tried entacapone and according to the prescriber, experienced significant intolerance or inadequate efficacy.

## **PART B PREREQUISITE**

N/A

## **TOPICAL\_RETINOID**

---

### **MEDICATION(S)**

AVITA 0.025 % CREAM, TAZAROTENE 0.05 % GEL, TAZAROTENE 0.1 % CREAM, TAZAROTENE 0.1 % GEL, TRETINOIN 0.01 % GEL, TRETINOIN 0.025 % CREAM, TRETINOIN 0.025 % GEL, TRETINOIN 0.05 % CREAM, TRETINOIN 0.05 % GEL, TRETINOIN 0.1 % CREAM

### **PA INDICATION INDICATOR**

3 - All Medically-Accepted Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Coverage is not provided for cosmetic use.

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# TRACLEER

---

## **MEDICATION(S)**

BOSENTAN

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Diagnosis confirmed by right heart catheterization.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **TRANSDERMAL\_FENTANYL**

---

### **MEDICATION(S)**

FENTANYL 100 MCG/HR PATCH 72HR, FENTANYL 12 MCG/HR PATCH 72HR, FENTANYL 25 MCG/HR PATCH 72HR, FENTANYL 50 MCG/HR PATCH 72HR, FENTANYL 75 MCG/HR PATCH 72HR

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

Acute (i.e., non-chronic) pain.

### **REQUIRED MEDICAL INFORMATION**

Pain type (chronic vs acute), prior pain medications/therapies tried, concurrent pain medications/therapies

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

'For pain severe enough to require daily, around-the-clock, long-term opioid treatment, approve if all of the following criteria are met: 1) patient is not opioid naive, AND 2) non-opioid therapies have been tried and are being used in conjunction with opioid therapy according to the prescribing physician, AND 3) the prescribing physician has checked the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP), AND 4) the prescribing physician has discussed risks (eg, addiction, overdose) and realistic benefits of opioid therapy with the patient, AND 5) according to the prescriber physician there is a treatment plan (including goals for pain and function) in place and reassessments are scheduled at regular intervals. Patients with cancer, sickle cell

disease, in hospice or who reside in a long term care facility are not required to meet above criteria. Clinical criteria incorporated into the quantity limit edits for all oral long-acting opioids (including transdermal fentanyl products) require confirmation that the indication is intractable pain (ie, FDA labeled use) prior to reviewing for quantity exception.

**PART B PREREQUISITE**

N/A



## **TRANSMUCOSAL\_FENTANYL**

---

### **MEDICATION(S)**

FENTANYL CITRATE 1200 MCG LOZ HANDLE, FENTANYL CITRATE 1600 MCG LOZ HANDLE, FENTANYL CITRATE 200 MCG LOZ HANDLE, FENTANYL CITRATE 400 MCG LOZ HANDLE, FENTANYL CITRATE 600 MCG LOZ HANDLE, FENTANYL CITRATE 800 MCG LOZ HANDLE

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

For breakthrough pain in patients with cancer if patient is unable to swallow, has dysphagia, esophagitis, mucositis, or uncontrollable nausea/vomiting OR patient is unable to take 2 other short-acting narcotics (eg, oxycodone, morphine sulfate, hydromorphone, etc) secondary to allergy or severe adverse events AND patient is on or will be on a long-acting narcotic (eg, Duragesic), or the patient is on intravenous, subcutaneous, or spinal (intrathecal, epidural) narcotics (eg, morphine sulfate, hydromorphone, fentanyl citrate). Clinical criteria incorporated into the quantity limit edits for all transmucosal fentanyl drugs require confirmation that the indication is breakthrough cancer pain (ie, FDA labeled use) prior to reviewing for quantity exception.

**PART B PREREQUISITE**

N/A

# **TRIKAFTA**

---

## **MEDICATION(S)**

TRIKAFTA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# TRUQAP

---

## **MEDICATION(S)**

TRUQAP

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of PIK3CA, AKT1, or PTEN alteration.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# TUKYSA

---

## **MEDICATION(S)**

TUKYSA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# TURALIO

---

## **MEDICATION(S)**

TURALIO 125 MG CAP

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **TYENNE**

---

### **MEDICATION(S)**

TYENNE 162 MG/0.9ML SOLN A-INJ, TYENNE 162 MG/0.9ML SOLN PRSYR

### **PA INDICATION INDICATOR**

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

### **OFF LABEL USES**

Systemic sclerosis-associated interstitial lung disease

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

For rheumatoid arthritis (initial requests): Two of the following were ineffective or not tolerated: a) Enbrel, b) Humira or Hadlima, c) Rinvoq OR d) Xeljanz. For polyarticular juvenile idiopathic arthritis (initial requests): Two of the following were ineffective or not tolerated: a) Humira or Hadlima, b) Enbrel OR c) Xeljanz. For giant cell arteritis (all requests): Trial of other agents not required. For systemic sclerosis-associated interstitial lung disease (initial requests): a) Diagnosis is confirmed with documentation provided of both of the following: i) HRCT scan AND ii) pulmonary function tests AND b) Trial of mycophenolate was ineffective or not tolerated. For systemic juvenile idiopathic arthritis (all requests): Trial of other agents not required. For continuation requests (all diagnoses): Member has benefited with use of this medication.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

For rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and giant cell arteritis: Prescribed by, or in consultation with, a rheumatology specialist. For systemic sclerosis-associated interstitial lung disease: Prescribed by, or in consultation with, a pulmonologist.

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

**PART B PREREQUISITE**

N/A



# TYKERB

---

## MEDICATION(S)

LAPATINIB DITOSYLATE

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# UCERIS

---

## **MEDICATION(S)**

BUDESONIDE 2 MG FOAM, BUDESONIDE 2 MG/ACT FOAM, BUDESONIDE ER

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Trial of mesalamine was ineffective or not tolerated.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# UPTRAVI

---

## **MEDICATION(S)**

UPTRAVI 1000 MCG TAB, UPTRAVI 1200 MCG TAB, UPTRAVI 1400 MCG TAB, UPTRAVI 1600 MCG TAB, UPTRAVI 200 & 800 MCG TAB THPK, UPTRAVI 200 MCG TAB, UPTRAVI 400 MCG TAB, UPTRAVI 600 MCG TAB, UPTRAVI 800 MCG TAB

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Diagnosis confirmed by right heart catheterization.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# VALCHLOR

---

## MEDICATION(S)

VALCHLOR

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# **VANFLYTA**

---

## **MEDICATION(S)**

VANFLYTA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of an FLT3 internal tandem duplication (ITD) mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# VENCLEXTA

---

## **MEDICATION(S)**

VENCLEXTA, VENCLEXTA STARTING PACK

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# VERKAZIA

---

## MEDICATION(S)

VERKAZIA

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

Diagnosis

## AGE RESTRICTION

4 years and older

## PRESCRIBER RESTRICTION

Prescribed by or in consultation with an optometrist or ophthalmologist

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

Vernal keratoconjunctivitis-approve if the patient has moderate to severe vernal keratoconjunctivitis and has tried one other ophthalmic medication for the maintenance treatment of vernal keratoconjunctivitis. Note: Examples of other ophthalmic medications for the maintenance treatment of vernal keratoconjunctivitis include ophthalmic antihistamines and ophthalmic mast-cell stabilizers (e.g., Iodoxamide tromethamine 0.1% ophthalmic solution). A previous trial of one ophthalmic cyclosporine product (e.g., Cequa [cyclosporine 0.09% ophthalmic solution], Restasis [cyclosporine 0.05% ophthalmic emulsion]) other than the requested drug also counts as a trial of one agent for vernal keratoconjunctivitis.

## PART B PREREQUISITE

N/A





# VERQUVO

---

## **MEDICATION(S)**

VERQUVO

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# VERZENIO

---

## MEDICATION(S)

VERZENIO

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

N/A

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

N/A

## COVERAGE DURATION

Approved for duration of 1 year.

## OTHER CRITERIA

N/A

## PART B PREREQUISITE

N/A

# VIJOICE

---

## **MEDICATION(S)**

VIJOICE 125 MG TAB THPK, VIJOICE 200 & 50 MG TAB THPK, VIJOICE 50 MG TAB THPK

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of mutation in the PIK3CA gene. For continuation requests: Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# VITRAKVI

---

## **MEDICATION(S)**

VITRAKVI

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of NTRK gene fusion mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# VIZIMPRO

---

## **MEDICATION(S)**

VIZIMPRO

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of appropriate EGFR mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# VONJO

---

## **MEDICATION(S)**

VONJO

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# VORICONAZOLE

---

## **MEDICATION(S)**

VORICONAZOLE 200 MG TAB, VORICONAZOLE 50 MG TAB, VORICONAZOLE 200 MG RECON SOLN, VORICONAZOLE 40 MG/ML RECON SUSP

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for 6 months.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# VOSEVI

---

## MEDICATION(S)

VOSEVI

## PA INDICATION INDICATOR

1 - All FDA-Approved Indications

## OFF LABEL USES

N/A

## EXCLUSION CRITERIA

N/A

## REQUIRED MEDICAL INFORMATION

1) Current HCV-RNA titer is provided 3) Member does not have decompensated cirrhosis 3) Previous Hepatitis C treatment(s) is provided.

## AGE RESTRICTION

N/A

## PRESCRIBER RESTRICTION

Prescribed by, or in consultation with, a gastroenterologist, hepatologist, or infectious disease or transplant specialist.

## COVERAGE DURATION

Coverage duration of 12 weeks.

## OTHER CRITERIA

Treatment regimen will be approved based on previous treatment experience as defined by current AASLD guidelines.

## PART B PREREQUISITE

N/A



## **VOTRIENT**

---

### **MEDICATION(S)**

PAZOPANIB HCL

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

## **WELIREG**

---

### **MEDICATION(S)**

WELIREG

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# **XALKORI**

---

## **MEDICATION(S)**

XALKORI

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of ALK-positive or ROS1-positive disease.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **XCOPRI**

---

## **MEDICATION(S)**

XCOPRI, XCOPRI (250 MG DAILY DOSE) 100 & 150 MG TAB THPK, XCOPRI (350 MG DAILY DOSE)

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Two of the following were ineffective or not tolerated: a) lamotrigine b) carbamazepine c) levetiracetam d) oxcarbazepine e) phenytoin f) topiramate OR g) lacosamide.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **XDEMZY**

---

## **MEDICATION(S)**

XDEMZY

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

Demodex blepharitis: Prescribed by or in consultation with an optometrist or ophthalmologist

## **COVERAGE DURATION**

Approved for duration of 6 weeks

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **XELJANZ**

---

## **MEDICATION(S)**

XELJANZ, XELJANZ XR

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For rheumatoid arthritis (initial requests): One of the following was ineffective or not tolerated: a) Humira or Hadlima OR b) Enbrel. For juvenile idiopathic arthritis (initial requests): One of the following was ineffective or not tolerated: a) Humira or Hadlima OR b) Enbrel. For psoriatic arthritis (initial requests): One of the following was ineffective or not tolerated: a) Humira or Hadlima OR b) Enbrel. For ankylosing spondylitis (initial requests): One of the following was ineffective or not tolerated: a) Humira or Hadlima OR b) Enbrel. For ulcerative colitis (initial requests): Failure of, or intolerance to Humira or Hadlima. For continuation requests (all diagnoses): Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

For rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, or psoriatic arthritis: Prescribed by, or in consultation with a rheumatology specialist. For ulcerative colitis : Prescribed by, or in consultation with a gastroenterologist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

## **XERMELO**

---

### **MEDICATION(S)**

XERMELO

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A



## **XGEVA**

---

### **MEDICATION(S)**

XGEVA

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

## **XIFAXAN 550MG**

---

### **MEDICATION(S)**

XIFAXAN 550 MG TAB

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

For diagnosis of IBS-D, approval will increase quantity limit to 42 tablets over 14 days, maximum of three fills per 1 year.

### **PART B PREREQUISITE**

N/A

# **XOLAIR**

---

## **MEDICATION(S)**

XOLAIR

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For initial requests: For asthma: History within the last year of at least 1 asthma exacerbation requiring one of the following, despite regular use of inhaled corticosteroids plus an additional controller(s): a) treatment with systemic corticosteroids, b) emergency department visit OR c) hospitalization. For chronic idiopathic urticaria: one of the following: a) patient remains symptomatic despite H1 antihistamine treatment OR b) has intolerance or contraindication to H1 antihistamine treatment. For nasal polyps: A) Confirmed diagnosis of nasal polyps (see other criteria) AND B) Trial of Dupixent was ineffective or not tolerated. For IgE-mediated food allergy: Confirmed diagnosis of IgE-mediated food allergy (see other criteria). For continuation requests (all diagnoses): Member has benefited with use of this medication.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

For asthma: Prescribed by, or in consultation with an allergist, pulmonologist, or immunologist. For chronic idiopathic urticaria: Prescribed by, or in consultation with an allergist, dermatologist, or immunologist. For nasal polyps: Prescribed by, or in consultation with, an allergist, immunologist, or otolaryngologist. For IgE-mediated food allergy: Prescribed by, or in consultation with an allergist or immunologist.

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

For asthma (initial requests): Documentation of diagnosis via skin test or RAST for specific allergy sensitivity. For nasal polyps (initial requests): Diagnosis is confirmed with a sinus CT scan AND at least four of the following apply: a) prior surgery for bilateral nasal polyposis b) evidence of type 2 inflammation c) two or more courses of oral corticosteroids required in the prior year d) significantly impaired quality of life e) significant loss of smell f) diagnosis of comorbid asthma. For IgE-mediated food allergy (initial requests): Both of the following: a) diagnosis supported by one of the following: i) positive skin prick test or ii) positive serum IgE test and b) diagnosis confirmed by one of the following: i) positive oral food challenge or ii) history of anaphylaxis to the suspected food allergen. For asthma (all requests): Will not be used in combination with another targeted immunomodulator product for the prescribed indication. For IgE-mediated food allergy (all requests): Will not be used in combination with peanut allergen powder (Palforzia).

## **PART B PREREQUISITE**

N/A

## **XOSPATA**

---

### **MEDICATION(S)**

XOSPATA

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Documentation is provided of FLT3 mutation.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

# XPOVIO

---

## **MEDICATION(S)**

XPOVIO (100 MG ONCE WEEKLY) 50 MG TAB THPK, XPOVIO (40 MG ONCE WEEKLY) 40 MG TAB THPK, XPOVIO (40 MG TWICE WEEKLY) 40 MG TAB THPK, XPOVIO (60 MG ONCE WEEKLY) 60 MG TAB THPK, XPOVIO (60 MG TWICE WEEKLY), XPOVIO (80 MG ONCE WEEKLY) 40 MG TAB THPK, XPOVIO (80 MG TWICE WEEKLY)

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **XTANDI**

---

## **MEDICATION(S)**

XTANDI

## **PA INDICATION INDICATOR**

4 - All FDA-Approved Indications, Some Medically-Accepted Indications

## **OFF LABEL USES**

Homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer in combination with Talzenna.

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer: Trial of abiraterone was ineffective or not tolerated. For nonmetastatic castration-resistant prostate cancer: Both of the following were ineffective or not tolerated: a) Nubeqa and b) Erleada. For non metastatic castration sensitive prostate cancer with biochemical recurrence at high risk for metastasis: Trial of other agents not required. For homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer in combination with Talzenna: Trial of other agents not required.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# **XYREM**

---

## **MEDICATION(S)**

SODIUM OXYBATE

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

For excessive daytime sleepiness with narcolepsy in adults: Both of the following were ineffective or not tolerated: a) Sunosi AND b) either modafinil or armodafinil. Trial of other agents not required for patients aged 7 to 17 years. For cataplexy with narcolepsy: Trial of other agents not required.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

For excessive daytime sleepiness with narcolepsy: Documentation is provided of full nocturnal polysomnogram used to confirm diagnosis. For cataplexy with narcolepsy: Documentation is provided of one of the following to confirm diagnosis: a) full nocturnal polysomnogram OR b) low cerebrospinal fluid orexin-A concentration.

## **PART B PREREQUISITE**

N/A



## **XYWAV**

---

### **MEDICATION(S)**

XYWAV

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

For excessive daytime sleepiness with narcolepsy in adults: Both of the following were ineffective or not tolerated: a) Sunosi AND b) either modafinil or armodafinil. Trial of other agents not required for patients aged 7 to 17 years. For cataplexy with narcolepsy: Trial of other agents not required. For idiopathic hypersomnia: Trial of modafinil was ineffective or not tolerated.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

For excessive daytime sleepiness with narcolepsy and idiopathic hypersomnia: Documentation is provided of full nocturnal polysomnogram used to confirm diagnosis. For cataplexy with narcolepsy: Documentation is provided of one of the following to confirm diagnosis: a) full nocturnal polysomnogram OR b) low cerebrospinal fluid orexin-A concentration.

### **PART B PREREQUISITE**

N/A

# **ZEJULA**

---

## **MEDICATION(S)**

ZEJULA

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

N/A

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# ZELBORAF

---

## **MEDICATION(S)**

ZELBORAF

## **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

## **OFF LABEL USES**

N/A

## **EXCLUSION CRITERIA**

N/A

## **REQUIRED MEDICAL INFORMATION**

Documentation is provided of appropriate BRAF V600E or V600 mutation.

## **AGE RESTRICTION**

N/A

## **PRESCRIBER RESTRICTION**

N/A

## **COVERAGE DURATION**

Approved for duration of 1 year.

## **OTHER CRITERIA**

N/A

## **PART B PREREQUISITE**

N/A

# ZOLINZA

---

**MEDICATION(S)**

ZOLINZA

**PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

**OFF LABEL USES**

N/A

**EXCLUSION CRITERIA**

N/A

**REQUIRED MEDICAL INFORMATION**

N/A

**AGE RESTRICTION**

N/A

**PRESCRIBER RESTRICTION**

N/A

**COVERAGE DURATION**

Approved for duration of 1 year.

**OTHER CRITERIA**

N/A

**PART B PREREQUISITE**

N/A

## **ZTALMY**

---

### **MEDICATION(S)**

ZTALMY

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Documentation is provided of a CDKL5 gene mutation

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

Prescribed by, or in consultation with, a neurologist.

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

## **ZURZUVAE**

---

### **MEDICATION(S)**

ZURZUVAE

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

N/A

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for 1 month.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A

## ZYDELIG

---

### MEDICATION(S)

ZYDELIG

### PA INDICATION INDICATOR

1 - All FDA-Approved Indications

### OFF LABEL USES

N/A

### EXCLUSION CRITERIA

N/A

### REQUIRED MEDICAL INFORMATION

N/A

### AGE RESTRICTION

N/A

### PRESCRIBER RESTRICTION

N/A

### COVERAGE DURATION

Approved for duration of 1 year.

### OTHER CRITERIA

N/A

### PART B PREREQUISITE

N/A

## ZYKADIA

---

### **MEDICATION(S)**

ZYKADIA

### **PA INDICATION INDICATOR**

1 - All FDA-Approved Indications

### **OFF LABEL USES**

N/A

### **EXCLUSION CRITERIA**

N/A

### **REQUIRED MEDICAL INFORMATION**

Documentation is provided of ALK-positive disease.

### **AGE RESTRICTION**

N/A

### **PRESCRIBER RESTRICTION**

N/A

### **COVERAGE DURATION**

Approved for duration of 1 year.

### **OTHER CRITERIA**

N/A

### **PART B PREREQUISITE**

N/A